Kala Bio Inc (NAS:KALA)
$ 6.865 0.0486 (0.71%) Market Cap: 19.34 Mil Enterprise Value: 4.63 Mil PE Ratio: 0 PB Ratio: 2.51 GF Score: 51/100

Kala Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 03:15PM GMT
Release Date Price: $294 (-0.34%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Happy to introduce Kala Pharmaceuticals. I'm Tazeen Ahmad, the senior biotech analyst here at Bank of America. Speaking for Kala this morning is Mark Iwicki, Chairman and CEO. I'll turn the stage over to Mark and he's going to go over the slides of the pipeline overview. Thanks, Mark.

Mark T. Iwicki
Kala Pharmaceuticals, Inc. - Chairman, President & CEO

Thank you, Tazeen. Good morning, everyone. Thanks for being here this morning. I will be making some forward-looking statements, so here is our safe harbor statement. So Kala Pharmaceuticals is a company that is founded on our AMPPLIFY technology. And what we are able to do is selectively engineer particles to a specific size that helps them get through the mucus membranes in the eye. But in addition to that certain nanoparticle size, we actually coat the outside of each particle with a coating that further enhances their ability to very smoothly get through the mucus membranes. And not only do we get more drug through mucus and the mucous layers but

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot